Searched for
LONG LASTING STERILITY
For investors with ability to understand and take risks: 6 small-caps from different sectors with upside potential of up to 26%The mood across global markets is not great at this point of time. News headlines point in directions we would rather they did not. But suc...- Spain: Pope Leo says world crying for peace, urges leaders to temper divisionsPope Leo has begun a week-long visit to Spain on Saturday. He called on world leaders to reject divisive politics and embrace peace. The Po...
- For risk-takers with long-term perspective: 10 small-cap stocks from different sectors with upside potential of up to 31%If you buy small-cap stocks today, are you taking a risk or managing it? To some it might appear you are taking a risk, but there is a high...
- Why Some Parents in Finland Want Their Kids to Play in Dirt AgainA Finnish study transformed daycare playgrounds into biodiverse natural habitats, replacing traditional equipment with soil, plants, and fo...
- In war, anything can happen; in investing, only management matters. 6 stocks from different sectors with upside potential of up to 27%Net margin is a useful metric. It tells you how much profit remains after costs, interest, and tax are deducted from revenue. But it does n...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...
- Millions of flies to rain from US planes? Here’s why Washington may make this wild moveThe United States has temporarily closed its southern border to livestock imports due to the northward spread of the New World screwworm fl...
- Long-lasting, reversible contraceptive for men coming soon. ICMR study shows promising resultsICMR has conducted a groundbreaking study on male contraception and found that a non-hormonal injectable contraceptive called RISUG is both...
- Gland Pharma falls 5% after announcing Cenexi Group acquisitionCenexi, along with its subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of ph...
- Abu Dhabi announces sudden overnight lockdownThe state-run WAM news agency announced late Thursday the lockdown would begin Monday and last each day from 12 a.m. to 5 a.m. It comes jus...
- China forces birth control on Uighurs to suppress populationThe campaign over the past four years in the far west region of Xinjiang is leading to what some experts are calling a form of "demographic...
- 2020 to prove disappointing for Indian pharma: Amit RajanSun Pharma, Lupin and others are falling apart on injectable inspections and this is where the problem starts.
- Pharma cos staring at some margin pressure: Surajit Pal, Prabhudas Lilladher"Non-sterile plants getting stuck for such a long time are really surprising."
- Pharma cos have not worked on compliance issues: Amit Rajan, Prosfora TechConcern remains over Indian pharma’s sterile manufacturing practices, says Prosfora Tech MD
- Swelling forex reserves could soon cost RBI in ways very few foresawThe pressing need to absorb both dollar and rupee liquidity is already stretching the Reserve Bank of India’s range of tools and complicati...
- Swedish firm Recipharm buys majority stake in Nitin Lifesciences for Rs 671 croreSwedish contract drug manufacturing firm Recipharm has acquired a 74% stake in Nitin Lifesciences, a privately held sterile injectables man...
- Government to go ahead with birth control injectionsDrugs Technical Advisory Board's recommendations are based on studies conducted by the ICMR in India for injectable contraceptives.
- Pfizer buying Hospira for about $15.23 billionPfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its global established pharmaceutical business.
- Durbar resumes in a peaceful Srinagar for six monthsAs durbar resumes functioning in Srinagar for the six-month stint, Kashmir is cool and normal.
- Aurobindo to suffer $2-mn loss per month due to USFDA banAurobindo Pharma said they may incur a revenue loss to the extent of $2 million per month till the issue remains unresolved.
Load More
